C$0.455 0.0 3.4%
Last Trade - 8:59pm
| Market Cap | ÂŁ17.9m |
| Enterprise Value | ÂŁ17.5m |
| Revenue | ÂŁn/a |
| Position in Universe | 1333rd / 2679 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Oct | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Biovaxys Technology Corp., formerly Lions Bay Mining Corp., is a Canada-based clinical-stage immunotherapeutics company. The Company develops vaccine platforms for SARS-CoV-2 and various cancers.
| Last Annual | October 31st, 2019 |
| Last Interim | July 31st, 2020 |
| Incorporated | April 25, 2018 |
| Public Since | November 21, 2018 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Canadian Securities Exchange |
| Shares in Issue | 71,203,091 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 503 - 905 West Pender Street, VANCOUVER, V6C 1L6, Canada |
| Web | https://biovaxys.com/ |
| Phone | +1 604 2628835 |
| Contact | () |
| Auditors | Dale Matheson Carr-Hilton LaBonte LLP |
As of 8:59pm, shares in Biovaxys Technology are trading at C$0.455, giving the company a market capitalisation of ÂŁ17.9m. This share price information is delayed by 15 minutes.
Shares in Biovaxys Technology are currently trading at C$0.455 and the price has moved by 0.878k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biovaxys Technology price has moved by 0.773k% over the past year.
There are no analysts currently covering Biovaxys Technology.
Biovaxys Technology is scheduled to issue upcoming financial results on the following dates:
Biovaxys Technology does not currently pay a dividend.
Biovaxys Technology does not currently pay a dividend.
Biovaxys Technology does not currently pay a dividend.
To buy shares in Biovaxys Technology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biovaxys Technology are currently trading at C$0.455, giving the company a market capitalisation of ÂŁ17.9m.
Here are the trading details for Biovaxys Technology:
Based on an overall assessment of its quality, value and momentum, Biovaxys Technology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for Biovaxys Technology.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biovaxys Technology. Over the past six months, the relative strength of its shares against the market has been 39.58%. At the current price of C$0.455, shares in Biovaxys Technology are trading at 85.25% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Biovaxys Technology.
We were unable to find the directors for Biovaxys Technology.
Here are the top five shareholders of Biovaxys Technology based on the size of their shareholding:
